FGF23 and chronic kidney disease: The main finding of this study is that in post-myocardial infarction patients with chronic kidney disease (eGFR < 60 mL/min/1.73 m2), low dose n-3 fatty acid supplementation did not reduce plasma C-terminal FGF23 levels.